Products - Oesophageal cancer | Topic | NICE

Showing 6 products

Date | Title

Status: Awaiting developmentRemove ‘Status: Awaiting development’ filter

Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer [ID6481]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
13 January 2027
Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Domvanalimab with zimberelimab for untreated unresectable advanced gastric, gastro-oesophageal junction or oesophageal cancer [ID6606]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC